Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.7K

TES inhibits colorectal cancer progression through activation of p38

Huili Li1, Kun Huang2, Lu Gao3

  • 1Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Oncotarget
|June 22, 2016
PubMed

Insights

The TESTIN (TES) gene suppresses colorectal cancer (CRC) progression by activating p38-MAPK pathways. Reduced TES levels promote CRC, suggesting TES as a potential therapeutic target for colon cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The TESTIN (TES) gene is a candidate tumor suppressor located at a common fragile site.
  • Loss of heterozygosity at this site is observed in various tumors, prompting investigation into its role in colorectal cancer (CRC).

Purpose of the Study:

  • To investigate the role of the TESTIN (TES) gene in colorectal cancer (CRC) progression.
  • To determine the effect of TES protein levels on CRC cell behavior and signaling pathways.

Main Methods:

  • Examined TES protein levels in CRC tissues and cell lines.
  • Utilized gene overexpression and shRNA-mediated knockdown to assess TES function in colon cancer cells.
  • Analyzed the impact of TES on apoptosis, proliferation, migration, invasion, and p38 MAPK signaling.

Main Results:

  • TES protein levels were significantly reduced in CRC tissues and cell lines.
  • Overexpression of TES inhibited CRC cell proliferation, migration, and invasion, while promoting apoptosis.
  • TES knockdown produced opposite effects, increasing CRC progression.
  • TES functions by up-regulating pro-apoptotic proteins, down-regulating anti-apoptotic proteins, and activating p38 MAPK signaling.

Conclusions:

  • TESTIN (TES) acts as a crucial suppressor of colorectal cancer progression.
  • TES exerts its tumor-suppressive function through the activation of p38-MAPK signaling pathways.
  • TES holds potential for CRC diagnosis and targeted gene therapy.
Keywords:
HCT116 cell and DLD-1 cellTESTIN genecolorectal cancerp38 MAP kinasetumor suppressor gene

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.8K